InvestorsFund performance: Mid-life funds benefit from biotech, tech upswingsBig gains seen by ARCH, Pacven, Advanced TechByMark Boslet15 September 2015•1 min readJavaScript is required to read this article. Please enable it in your browser and reload the page.InvestorsInvestor PerformancePerformance